Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenolsulphonic Acid SCHEMBL11055660 | 0.96 | HSD17B10 (0.45) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL21332482 | 0.93 | AURKA (0.38) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL374828 | 0.92 | AURKA (0.43) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL9786237 | 0.90 | ALDH1A1 (0.43) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL20241152 | 0.90 | AURKA (0.42) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL16045143 | 0.87 | AURKA (0.47) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL29449532 | 0.87 | SMN1; SMN2 (0.46) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL11154671 | 0.87 | SMN1; SMN2 (0.46) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL18274 | 0.87 | SMN1; SMN2 (0.46) | AURKAAURKBHSD17B10ALDH1A1TSHR | |
| Phenolsulphonic Acid SCHEMBL3173401 | 0.85 | AURKA (0.46) | AURKAAURKBHSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107389-B1 | AQUEOUS CO-FORMULATION OF METALAXYL | BASF SE (DE) | 2021-07-21 | — | — | EP | claimed |
| US-20210186018-A1 | Aqueous Co-Formulation of Metalaxyl | BASF SE (DE) | 2021-06-24 | — | — | US | claimed |
| US-20170055527-A1 | Aqueous Co-Formulation of Metalaxyl | BASF SE (DE) | 2017-03-02 | — | — | US | claimed |
| EP-3107389-A1 | AQUEOUS CO-FORMULATION OF METALAXYL | BASF SE (DE) | 2016-12-28 | — | — | EP | claimed |
| WO-2015124662-A1 | AQUEOUS CO-FORMULATION OF METALAXYL | BASF SE (DE) | 2015-08-27 | — | — | WO | claimed |
| US-20240008484-A1 | Aqueous Co-Formulation of Metalaxyl | BASF SE (DE) | 2024-01-11 | — | — | US | disclosed |
| EP-3908584-B1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-4008185-A1 | HERBICIDAL COMPOSITION COMPRISING A SAFLUFENACIL MICROPARTICLES | BASF Agro B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| US-11317628-B2 | Microparticle compositions comprising saflufenacil | BASF Agro B.V. (NL) | 2022-05-03 | — | — | US | disclosed |
| US-20220024898-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2022-01-27 | — | — | US | disclosed |
| EP-3908584-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3107389-B1 | AQUEOUS CO-FORMULATION OF METALAXYL | BASF SE (DE) | 2021-07-21 | — | — | EP | disclosed |
| US-8309769-B2 | Crystalline forms of 2-[2-chloro-4-methylsulfony1-3-(2,2,2-trifluoroethoxymethyl)benzoyl]cyclohexan-1,3-dione | BASF SE (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8101780-B2 | Crystalline form of 3-(difluormethyl)-1-methyl-N-(3′,4′,5′-trifluor[1,1′-biphenyl]-2-yl)-1H-pyrazol-4-carboxamide | BASF SE (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20100255996-A1 | Novel crystalline form of 3-(Difluormethyl)-1-methyl-N -(3',4',5'-trifluor[1,1'-biphenyl]-2-yl)-1H-pyrazol-4-carboxamide | BASF SE (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100041557-A1 | Crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoroethoxymethyl)benzoyl]cyclohexan-1,3-dione | BASF SE (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2137142-A1 | CRYSTALLINE FORMS OF 2-Ý2-CHLORO-4-METHYLSULFONYL-3-(2,2,2-TRIFLUOROETHOXYMETHYL)BENZOYL¨CYCLOHEXAN-1,3-DIONE | BASF SE (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110621-A1 | CRYSTALLINE FORMS OF 2-[2-CHLORO-4-METHYLSULFONYL-3-(2,2,2-TRIFLUOROETHOXYMETHYL)BENZOYL]CYCLOHEXAN-1,3-DIONE | BASF SE (DE) | 2008-09-18 | — | — | WO | disclosed |
| US-6494924-B1 | Precipitated water-insoluble colorants in colloid disperse form | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-17 | — | — | US | disclosed |
| US-6090415-A | SYNERGISTIC MIXTURE | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024898-A1 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | CRY1, PRMT5, KDM5D | AURKA 2460/4885AURKB 3674/4885HSD17B10 4834/4885 |
| US-20100041557-A1 | Crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoroethoxymethyl)benzoyl]cyclohexan-1,3-dione | TCOF1, TBCD, TTI2 | AURKA 4396/4885AURKB 4450/4885HSD17B10 320/4885 |
| US-11317628-B2 | Microparticle compositions comprising saflufenacil | PMM2, AASDHPPT, APRT | AURKA 109/4885AURKB 376/4885HSD17B10 4073/4885 |
| US-20100255996-A1 | Novel crystalline form of 3-(Difluormethyl)-1-methyl-N -(3',4',5'-trifluor[1,1'-biphenyl]-2-yl)-1H-pyrazol-4-carboxamide | PML, NOD1, BROX | AURKA 3035/4885AURKB 4231/4885HSD17B10 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.